Home > Focus Areas > DLBCL Connect > Post

Lenalidomide in DLBCL: are we past the cell of origin? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33989279/
Single-agent lenalidomide has modest activity in diffuse large B-cell lymphoma (DLBCL) and is thought to be more potent in activated B-cell (ABC) lymphomas, which are more treatment-resistant. However, the addition of lenalidomide to rituximab plus cyclophosphamide, doxorubicin, vincristine, and pre ...
-
Mark FeslerMay 31, 2021A nice review on an important drug in Dlbcl in spite of some negative trials. The ability of this agent to induce and maintain very prolonged responses makes it a very valuable agent for a subset of these patients